Tema Etfs LLC Invests $237,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Tema Etfs LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, Holdings Channel.com reports. The fund acquired 11,352 shares of the biopharmaceutical company’s stock, valued at approximately $237,000.

A number of other institutional investors have also recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $27,000. Farther Finance Advisors LLC boosted its position in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $65,000. KBC Group NV boosted its position in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $104,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Finally, Stephens reaffirmed an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 351,879 shares of company stock worth $8,214,815. Insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $24.37 on Monday. The stock has a 50-day moving average of $23.23 and a two-hundred day moving average of $22.48. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The stock has a market cap of $2.97 billion, a P/E ratio of 20.65, a P/E/G ratio of 3.31 and a beta of 0.70.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.